Blockade of X4-tropic HIV-1 cellular entry by GSK812397, a potent noncompetitive CXCR4 receptor antagonist

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 2, 2010, Pages 817-824

  Jenkinson, Stephen ^a   Thomson, Michael ^a   McCoy, David ^a   Edelstein, Mark ^a   Danehower, Susan ^a   Lawrence, Wendell ^a   Wheelan, Pat ^a   Spaltenstein, Andrew ^a   Gudmundsson, Kristjan ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[5 (4 METHYL 1 PIPERAZINYL) 2 [[METHYL(5,6,7,8 TETRAHYDRO 8 QUINOLINYL)AMINO]METHYL]IMIDAZO[1,2 A]PYRIDIN 3 YL]METHANOL; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; GSK 812397; OROSOMUCOID; PLASMA PROTEIN; SERUM ALBUMIN; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CALCIUM TRANSPORT; CELL ASSAY; CHEMOTAXIS; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; EMBRYO; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VIRUS ENTRY; VIRUS INHIBITION; VIRUS STRAIN;

CELL LINE; CELL LINE, TUMOR; CELLS, CULTURED; CHEMOTAXIS; ENZYME ACTIVATION; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; RECEPTORS, CXCR4; VIRUS REPLICATION;

EID: 75749136043     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01293-09     Document Type: Article

References (26)

1. Reference deleted.
2. Boggs, S., V. I. Elitzin, K. Gudmundsson, M. T. Martin, and M. J. Sharp. 2009. Kilogram-scale synthesis of the CXCR4 antagonist GSK812397. Org. Process Res. Dev. doi:10.1021/op9000675.
3. Buckley, C. D., N. Amft, P. F. Bradfield, D. Pilling, E. Ross, F. Arenzana-Seisdedos, A. Amara, S. J. Curnow, J. M. Lord, D. Scheel-Toellner, and M. Salmon. 2000. Persistent induction of the chemokine receptor CXCR4 by TGF-ß1 on synovial T cells contributes to their accumulation within the rheumatoid synovium. J. Immunol. 165:3423-3429.
4. Conklin, B. R., Z. Farfel, K. D. Lustig, D. Julius, and H. R. Bourne. 1993. Substitution of three amino acids switches receptor specificity of Gq alpha to that of Gi alpha. Nature 363:274-276.
5. Deng, H., D. Unutmaz, V. N. Kewalramani, and D. R. Littman. 1997. Expression cloning of new receptors used by simian and human immunodefi-ciency viruses. Nature 388:296-300.
6. Dorr, P., M. Westby, S. Dobbs, P. Griffin, B. Irvine, M. Macartney, J. Mori, G. Rickett, C. Smith-Burchnell, C. Napier, R. Webster, D. Armour, D. Price, B. Stammen, A. Wood, and M. Perros. 2005. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49:4721-4732.
7. Hazen, R., R. Harvey, R. Ferris, C. Craig, P. Yates, P. Griffin, J. Miller, I. Kaldor, J. Ray, V. Samano, E. Furfine, A. Spaltenstein, M. Hale, R. Tung, M. St. Clair, M. Hanlon, and L. Boone. 2007. In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. Antimicrob. Agents Chemother. 51:3147-3154.
8. Hendrix, C. W., A. C. Collier, M. M. Lederman, D. Schols, R. B. Pollard, S. Brown, J. B. Jackson, R. W. Coombs, M. J. Glesby, C. W. Flexner, G. J. Bridger, K. Badel, R. T. MacFarland, G. W. Henson, and G. Calandra. 2004. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J. Acquir. Immune Defic. Syndr. 37:1253-1262.
9. Jenkinson, S., D. McCoy, S. Kerner, R. Ferris, W. Lawrence, T. Fox, and C. Smith. 2003. Development of a high-throughput viral-free assay for the measurement of CCR5-mediated HIV/cell fusion. Receptors Channels 9:117-123.
10. Lee, B., M. Sharron, L. J. Montaner, D. Weissman, and R. W. Doms. 1999. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc. Natl. Acad. Sci. U. S. A. 96:5215-5220.
11. Luckow, V. A., S. C. Lee, G. F. Barry, and P. O. Olins. 1993. Efficient generation of infectious recombinant baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome propagated in Escherichia coli. J. Virol. 67:4566-4579.
12. Reference deleted.
13. Matthews, T., M. Salgo, M. Greenberg, J. Chung, R. DeMasi, and D. Bolognesi. 2004. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat. Rev. Drug Discov. 3:215-225.
14. Matthys, P., S. Hatse, K. Vermeire, A. Wuyts, G. Bridger, G. W. Henson, E. De Clercq, A. Billiau, and D. Schols. 2001. AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-γ receptor-deficient mice. J. Immunol. 167:4686-4692.
15. Moyle, G., E. DeJesus, M. Boffito, R. S. Wong, C. Gibney, K. Badel, R. MacFarland, G. Calandra, G. Bridger, and S. Becker. 2009. Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1. Clin. Infect. Dis. 48:798-805.
16. Muller, A., B. Homey, H. Soto, N. Ge, D. Catron, M. E. Buchanan, T. McClanahan, E. Murphy, W. Yuan, S. N. Wagner, J. L. Barrera, A., Mohar, E. Verastegui, and A. Zlotnik. 2001. Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50-56.
17. Murakami, T., S. Kumakura, T. Yamazaki, R. Tanaka, M. Hamatake, K. Okuma, W. Huang, J. Toma, J. Komano, M. Yanaka, Y. Tanaka, and N. Yamamoto. 2009. The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100. Antimicrob. Agents Chemother. 53:2940-2948.
18. O'Reilly, D. R., L. K. Miller, and V. A. Luckow. 1992. Baculovirus expression vectors: a laboratory manual. Oxford University Press, New York, NY.
19. Petropoulos, C. J., N. T. Parkin, K. L. Limoli, Y. S. Lei, T. Wrin, W. Huang, H. Tian, D. Smith, G. A. Winslow, D. J. Capon, and J. M. Whitcomb. 2000. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44:920-928.
20. Schuitemaker, H., M. Koot, N. A. Kootstra, M. W. Dercksen, R. E. de Goede, R. P. van Steenwijk, J. M. Lange, J. K. Schattenkerk, F. Miedema, and M. Tersmette. 1992. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J. Virol. 66:1354-1360.
21. Reference deleted.
22. Scotton, C. J., J. L. Wilson, K. Scott, G. Stamp, G. D. Wilbanks, S. Fricker, G. Bridger, and F. R. Balkwill. 2002. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res. 62:5930-5938.
23. Shaheen, F., and R. G. Collman. 2004. Co-receptor antagonists as HIV-1 entry inhibitors. Curr. Opin. Infect. Dis. 17:7-16.
24. Verani, A., and P. Lusso. 2002. Chemokines as natural HIV antagonists. Curr. Mol. Med. 2:691-702.
25. Watson, C., S. Jenkinson, W. Kazmierski, and T. Kenakin. 2005. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol. Pharmacol. 67:1268-1282.
26. Zhu, T., H. Mo, N. Wang, D. S. Nam, Y. Cao, R. A. Koup, and D. D. Ho. 1993. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 261:1179-1181.